WO2016083490A1 - Compounds for the treatment of amyloid-associated diseases - Google Patents

Compounds for the treatment of amyloid-associated diseases Download PDF

Info

Publication number
WO2016083490A1
WO2016083490A1 PCT/EP2015/077731 EP2015077731W WO2016083490A1 WO 2016083490 A1 WO2016083490 A1 WO 2016083490A1 EP 2015077731 W EP2015077731 W EP 2015077731W WO 2016083490 A1 WO2016083490 A1 WO 2016083490A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
group
cycloalkyl
heterocyclyl
haloci
Prior art date
Application number
PCT/EP2015/077731
Other languages
English (en)
French (fr)
Inventor
Maxime Robin
Gilles Casano
Sébastien ABEL
Gerard Griffioen
Katrien PRINCEN
Veronica Rojas De La Parra
Original Assignee
Remynd Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remynd Nv filed Critical Remynd Nv
Publication of WO2016083490A1 publication Critical patent/WO2016083490A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
PCT/EP2015/077731 2014-11-27 2015-11-26 Compounds for the treatment of amyloid-associated diseases WO2016083490A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14195225.9 2014-11-27
EP14195225 2014-11-27

Publications (1)

Publication Number Publication Date
WO2016083490A1 true WO2016083490A1 (en) 2016-06-02

Family

ID=52016429

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2015/077731 WO2016083490A1 (en) 2014-11-27 2015-11-26 Compounds for the treatment of amyloid-associated diseases

Country Status (1)

Country Link
WO (1) WO2016083490A1 (j)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112300002A (zh) * 2020-10-26 2021-02-02 安徽工业大学 一种5-硝基丹皮酚及5-硝基丹皮酚腙的制备方法
US20220062274A1 (en) * 2020-09-01 2022-03-03 University Of South Florida Novel bronchodilators for treating obstructive lung disease

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3868378A (en) * 1973-06-06 1975-02-25 Morton Norwich Products Inc Imidazo {8 4,5-f{9 {0 quinolin-9-ols
EP0370498A2 (en) 1988-11-24 1990-05-30 Yoshitomi Pharmaceutical Industries, Ltd. Trans-4-amino(alkyl)-1-pyridylcarbamoylcyclohexane compounds and pharmaceutical use thereof
EP0721331A1 (en) 1993-10-01 1996-07-17 Astra Aktiebolag Process i
WO1999033793A2 (en) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
WO1999033795A1 (en) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
WO1999033815A1 (en) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors
WO1999033792A2 (en) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6369086B1 (en) 1997-09-05 2002-04-09 Smithkline Beecham Corporation Substituted oxidole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors
US6372778B1 (en) 1992-09-08 2002-04-16 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
US6372733B1 (en) 1995-11-01 2002-04-16 Merck & Co., Inc. Hexahydro-5-imino-1,4-1,4-thiazepine derivatives as inhibitors of nitric oxide synthases
WO2004089950A1 (de) * 2003-04-11 2004-10-21 Boehringer Ingelheim International Gmbh Tricyclische heteroaromatische verbindungen
US20040214833A1 (en) * 2003-04-11 2004-10-28 Boehringer Ingelheim International Gmbh Tricyclic heteroaromatic compounds
WO2006066955A1 (de) * 2004-12-22 2006-06-29 Bayer Schering Pharma Aktiengesellschaft Chinolinderivat, dessen verwendung, herstellung und dieses enthalten­des arzneimittel
WO2012050500A1 (en) * 2010-10-14 2012-04-19 Lars Pettersson 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as ahr activators.

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3868378A (en) * 1973-06-06 1975-02-25 Morton Norwich Products Inc Imidazo {8 4,5-f{9 {0 quinolin-9-ols
EP0370498A2 (en) 1988-11-24 1990-05-30 Yoshitomi Pharmaceutical Industries, Ltd. Trans-4-amino(alkyl)-1-pyridylcarbamoylcyclohexane compounds and pharmaceutical use thereof
US4997834A (en) 1988-11-24 1991-03-05 Yoshitomi Pharmaceutical Industries, Ltd. Trans-4-amino(alkyl)-1-pyridylcarbamoylcyclohexane compounds and pharmaceutical use thereof
US6372778B1 (en) 1992-09-08 2002-04-16 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
EP0721331A1 (en) 1993-10-01 1996-07-17 Astra Aktiebolag Process i
US6372733B1 (en) 1995-11-01 2002-04-16 Merck & Co., Inc. Hexahydro-5-imino-1,4-1,4-thiazepine derivatives as inhibitors of nitric oxide synthases
US6369086B1 (en) 1997-09-05 2002-04-09 Smithkline Beecham Corporation Substituted oxidole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors
WO1999033793A2 (en) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
WO1999033795A1 (en) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
WO1999033815A1 (en) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors
WO1999033792A2 (en) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
WO2004089950A1 (de) * 2003-04-11 2004-10-21 Boehringer Ingelheim International Gmbh Tricyclische heteroaromatische verbindungen
US20040214833A1 (en) * 2003-04-11 2004-10-28 Boehringer Ingelheim International Gmbh Tricyclic heteroaromatic compounds
WO2006066955A1 (de) * 2004-12-22 2006-06-29 Bayer Schering Pharma Aktiengesellschaft Chinolinderivat, dessen verwendung, herstellung und dieses enthalten­des arzneimittel
WO2012050500A1 (en) * 2010-10-14 2012-04-19 Lars Pettersson 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as ahr activators.

Non-Patent Citations (43)

* Cited by examiner, † Cited by third party
Title
"Goodman and Gilman's, The Pharmacological Basis of Therapeutics"
"Heterocycles", HETEROCYCLES, vol. 53, 2000, pages 387 - 395
BIOORGANIC AND MEDICINAL CHEMISTRY, vol. 12, no. 9, 2004, pages 2079 - 2098
BIOORGANIC AND MEDICINAL CHEMISTRY, vol. 15, no. 10, 2007, pages 3356 - 3367
BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN, vol. 61, 1988, pages 3008 - 3010
CHEMMEDCHEM, vol. 3, no. 10, 2008, pages 1572 - 1579
DARQUE A ET AL: "Synthesis and biological evaluation of new heterocyclic quinolinones as anti-parasite and anti-HIV drug candidates", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 19, no. 20, 15 October 2009 (2009-10-15), pages 5962 - 5964, XP026640612, ISSN: 0960-894X, [retrieved on 20090807], DOI: 10.1016/J.BMCL.2009.08.013 *
DETOMA ET AL.: "Misfolded Proteins in Alzheimer's Disease and Type II Diabetes", CHEM. SOC. REV., 2012, pages 608 - 621
DI GIORGIO ET AL: "DNA-damaging activity and mutagenicity of 16 newly synthesized thiazolo[5,4-a]acridine derivatives with high photo-inducible cytotoxicity", MUTATION RESEARCH. GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS, ELSEVIER, AMSTERDAM, NL, vol. 650, no. 2, 19 November 2007 (2007-11-19), pages 104 - 114, XP022459119, ISSN: 1383-5718 *
FITTON A O ET AL: "PHARMACOLOGICALLY ACTIVE 4-OXO-4H-CHROMEN-2-CARBOXYLIC ACIDS. PART II. THE SYNTHESIS OF 4-OXO-4H-CHROMEN-2-CARBOXYLIC ACIDS CONTAINING A FUSED IMIDAZOLE OR OXAZOLE RING", JOURNAL OF THE CHEMICAL SOCIETY, CHEMICAL COMMUNICATIONS, CHEMICAL SOCIETY. LETCHWORTH, GB, 1 January 1970 (1970-01-01), pages 2518 - 2522, XP008060742, ISSN: 0022-4936 *
FITTON A O ET AL: "Pharmacologically active 4-oxo-4H-chromene-2-carboxylic acids. III. Mechanistic aspects of the decomposition of ethyl 6-azido-4-oxo-4H-chromene 2-carboxylate", JOURNAL OF THE CHEMICAL SOCIETY, SECTION C: ORGANIC CHEMISTRY.>6015C, CHEMICAL SOCIETY. LETCHWORTH, GB, vol. 18, 1 January 1971 (1971-01-01), pages 3079 - 3081, XP009158187, ISSN: 0022-4952 *
GOODMAN; GILMAN: "The Pharmacological Basis of Therapeutics. 8th ed.", 1992, MCGRAW-HILL, INT. ED., article "Biotransformation of Drugs", pages: 13 - 15
H. G. BRITAIN: "Polymorphism in Pharmaceutical Solids", 1995, MARCEL DEKKER
HALEBLIAN, J PHARM SCI, vol. 64, no. 8, August 1975 (1975-08-01), pages 1269 - 1288
HELEYOVA KATARINA ET AL: "Gould-Jacobs reaction of 5- and 6-amino-2-substituted benzoxazoles. II. Reaction with 3-ethoxymethylene-2,4-pentanedione and ethyl 2-ethoxymethylene-3-oxobutanoate", COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNICATIONS, INSTITUTE OF ORGANIC CHEMISTRY & BIOCHEMISTRY, PRAGUE; CZ, vol. 61, no. 3, 1 January 1996 (1996-01-01), pages 371 - 380, XP009188362, ISSN: 0010-0765 *
HOUT, S. ET AL., PARASITOLOGY, vol. 129, no. 5, 2004, pages 525 - 535
INDIAN JOURNAL OF CHEMISTRY, vol. 44B, no. 12, 2005, pages 2601 - 2603
J. P. HANOUN ET AL: "1H and13C chemical shifts of some tetracyclic and pentacyclic acridinone derivatives", MAGNETIC RESONANCE IN CHEMISTRY, vol. 37, no. 1, 1 January 1999 (1999-01-01), pages 86 - 89, XP055170701, ISSN: 0749-1581, DOI: 10.1002/(SICI)1097-458X(199901)37:1<86::AID-MRC401>3.0.CO;2-F *
J.HETEROCYCL. CHEM., vol. 39, 2002, pages 1083 - 1085
JEAN-PIERRE HANOUN ET AL: "Azido/tetrazole equilibrium in the thiazoloacridinone series", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 33, no. 3, 1 January 1996 (1996-01-01), pages 747 - 750, XP055170678, DOI: 10.1002/jhet.5570330337 *
JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 34, no. 6, 1997, pages 1781 - 1787
JOURNAL OF MEDICINAL CHEMISTRY, vol. 39, no. 10, 1996, pages 1975 - 1980
JOURNAL OF MEDICINAL CHEMISTRY, vol. 50, no. 14, 2007, pages 3359 - 3368
JOURNAL OF ORGANIC CHEMISTRY, 1934, pages 31 - 52
JOURNAL OF ORGANIC CHEMISTRY, vol. 22, 1957, pages 304 - 306
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 60, 1938, pages 1370 - 1371
JOURNAL OF THE CHEMICAL SOCIETY OF JAPAN, vol. 55, 1934, pages 1256 - 1261
JULIEN DEBRAY ET AL: "Catalyst-free synthesis of quinazolin-4-ones from (hetero)aryl-guanidines: application to the synthesis of pyrazolo[4,3-]quinazolin-9-ones, a new family of DYRK1A inhibitors", MOLECULAR DIVERSITY, KLUWER ACADEMIC PUBLISHERS, DO, vol. 16, no. 4, 19 September 2012 (2012-09-19), pages 659 - 667, XP035144534, ISSN: 1573-501X, DOI: 10.1007/S11030-012-9397-7 *
MP LAMBERT ET AL., PROC. NAT 7 ACAD. SD. USA, vol. 95, 1998, pages 6448 - 6453
N. H. HARTSHORNE; A. STUART: "Crystals and the Polarizing Microscope. 4tzh ed.", 1970, EDWARD ARNOLD
NUVOLE A ET AL: "1,2,3-triazolo[4,5-f]quinolines. II. Preparation and antimicrobial evaluation of 6-ethyl-6,9-dihydro-1(2)(3)-R-1(2) (3)H-triazolo [4,5-f]quinolin-9-one-8-carboxylic acids as anti-infectives of the urinary tract (1)", IL FARMACO, ELSEVIER FRANCE * EDITIONS SCIENTIFIQUES ET MEDICALES, FR, vol. 44, no. 6, 1 June 1989 (1989-06-01), pages 619 - 632, XP009106308, ISSN: 0014-827X *
O. ALMARSSON; M. J. ZAWOROTKO, CHEM COMMUN, vol. 17, 2004, pages 1889 - 1896
RAKEZ KAYEDL; ELIZABETH HEAD2; JENNIFER L. THOMPSON; THERESA M. MCLNTIRE; SASKIA C. MILTON; CARL W. COTMAN; CHARLES G. GLABEL: "Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis", SCIENCE, vol. 300, no. 5618, 18 April 2003 (2003-04-18), pages 486 - 489
RÉMI GUILLON ET AL: "Discovery of a Novel Broad-Spectrum Antifungal Agent Derived from Albaconazole", ACS MEDICINAL CHEMISTRY LETTERS, vol. 4, no. 2, 14 February 2013 (2013-02-14), pages 288 - 292, XP055170769, ISSN: 1948-5875, DOI: 10.1021/ml300429p *
SCHNELLER S W ET AL: "SYNTHESIS OF PROXIMAL-BENZOGUANINE AND A SIMPLIFIED SYNTHESIS OF PROXIMAL-BENZOHYPOXANTHINE", THE JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 51, no. 21, 1 January 1986 (1986-01-01), pages 4067 - 4070, XP002920282, ISSN: 0022-3263, DOI: 10.1021/JO00371A029 *
STEWART W. SCHNELLER ET AL: "The synthesis of proximal -benzolumazine, proxirnal -benzoxanthine, proximal -benzotheophylline and proximal -benzocaffeine", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 18, no. 3, 1 May 1981 (1981-05-01), US, pages 653 - 654, XP055247177, ISSN: 0022-152X, DOI: 10.1002/jhet.5570180347 *
SYNLETT, 2007, pages 2687 - 2690
SYNTHESIS, 1979, pages 901 - 903
SYNTHETIC COMMUNICATIONS, vol. 40, 2010, pages 632 - 641
T. W. GREENE; P. G. M. WUTS: "Protective Groups in Organic Chemistry", 1999, JOHN WILEY AND SONS
TETRAHEDRON LETTERS, vol. 46, no. 21, 2005, pages 3707 - 3709
TETRAHEDRON LETTERS, vol. 46, no. 25, 2005, pages 4345 - 4347
TETRAHEDRON, vol. 61, no. 12, 2005, pages 3031 - 3017

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220062274A1 (en) * 2020-09-01 2022-03-03 University Of South Florida Novel bronchodilators for treating obstructive lung disease
CN112300002A (zh) * 2020-10-26 2021-02-02 安徽工业大学 一种5-硝基丹皮酚及5-硝基丹皮酚腙的制备方法

Similar Documents

Publication Publication Date Title
WO2017157882A1 (en) Serine biosynthetic pathway inhibitors
WO2007114213A1 (ja) 置換二環式環状誘導体及びその用途
US20200140400A1 (en) Oxadiazole compounds
JP2019147834A (ja) ２，７−ジアザスピロ［３．５］ノナン化合物
JP2023544719A (ja) がん治療のためのｙａｐ／ｔａｚ－ｔｅａｄ活性の阻害剤としての１，２，３，４－テトラヒドロキノリン誘導体
WO2016083490A1 (en) Compounds for the treatment of amyloid-associated diseases
MXPA05011242A (es) Compuestos isocromanos sustituidos para el tratamiento de trastornos metabolicos, cancer y otras enfermedades.
JP2013514325A (ja) ｍＧｌｕＲ５受容体のアロステリック調節因子としての二環式チアゾール
CA3218724A1 (en) 3-pyrrolylsulfonamide compounds as gpr17 antagonists
TW202342433A (zh) 用於抑制ｙａｐ／ｔａｚ—ｔｅａｄ之二氫喹唑啉酮及相關類似物
WO2023164596A1 (en) Dihydroquinazolinones and related analogs for inhibiting yap/taz-tead
WO2023122783A2 (en) Tetrahydropyrazolopyrimidines and related analogs for inhibiting yap/taz-tead
TW202334091A (zh) 用於抑制ｙａｐ／ｔａｚ－ｔｅａｄ之四氫苯并氮呯酮及相關類似物
TW202333691A (zh) 用於抑制ｙａｐ／ｔａｚ—ｔｅａｄ之螺化合物及相關類似物
WO2023122782A2 (en) Indoles, indazoles, and related analogs for inhibiting yap/taz-tead
WO2023122784A2 (en) Spiros and related analogs for inhibiting yap/taz-tead
WO2022184898A1 (en) Quinazolin-4-one and thieno[2,3-d]pyrimidin-4-one inhibitors of erbb4 (her4) for use in the treatment of cancer
US20230278962A1 (en) Tetrahydrobenzoazepinones and Related Analogs for Inhibiting YAP/TAZ-TEAD
TW202340150A (zh) 用於抑制ｙａｐ／ｔａｚ－ｔｅａｄ之吲哚、吲唑及相關類似物
NZ716609A (en) Fused piperidine amides as modulators of ion channels

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15807827

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15807827

Country of ref document: EP

Kind code of ref document: A1